Our investigation indicated that the treatment of MSC-TRAIL significantly enhanced the percentage of ΔΨ depolarization in CD133+ NSCLC-derived CSCs when compared to MSC-EV by 16.4-fold (3.0 ± 0.3% to 49.2 ± 2.5% in H460 cell line) and 3.6-fold (14.3 ± 0.3% to 51.1 ± 6.6% in H2170) (Figure 7A). The gene discussed is PROM1; the disease is non-small cell lung carcinoma.